ReP USP - Resultado da busca

Artigo de periodico
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017)
Ohman, E. Magnus; Roe, Matthew T.; Steg, P. Gabriel; James, Stefan K.; Povsic, Thomas J.; White, Jennifer; Rockhold, Frank; Plotnikov, Alexei; Mundl, Hardi; Strony, John; Sun, Xiang; Husted, Steen; Tendera, Michal; Montalescot, Gilles; Bahit, M. Cecilia; Ardissino, Diego; Bueno, Héctor; Claeys, Marc J.; Nicolau, Jose C.; Cornel, Jan H.; Goto, Shinya; Kiss, Róbert Gábor; Güray, Ümit; Park, Duk-Woo; Bode, Christoph; Welsh, Robert C.; Gibson, C. Michael
Fonte: Lancet. Unidade: FM
Assuntos: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICOAGULANTES, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OHMAN, E. Magnus et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, v. 389, n. 10081, p. 1799-1808, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)30751-1. Acesso em: 01 nov. 2024.
APA
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., et al. (2017). Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, 389( 10081), 1799-1808. doi:10.1016/S0140-6736(17)30751-1
NLM
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1
Vancouver
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1
Trabalho de evento-resumo periodico
P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes (2017)
Roe, Matthew T; Ohman, E. Magnus; Povsic, Thomas J; White, Jennifer; Rockold, Frank; Montalescot, Gilles; Cornel, Jan H; Nicolau, José Carlos; Steg, P. Gabriel; Gibson, C. Michael
Fonte: Circulation. Nome do evento: 2017 AHA Late-Breaking Sciences Abstracts. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, PLAQUETAS SANGUÍNEAS, CONDUTAS TERAPÊUTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROE, Matthew T et al. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1161/CIR.0000000000000546. Acesso em: 01 nov. 2024. , 2017
APA
Roe, M. T., Ohman, E. M., Povsic, T. J., White, J., Rockold, F., Montalescot, G., et al. (2017). P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. doi:10.1161/CIR.0000000000000546
NLM
Roe MT, Ohman EM, Povsic TJ, White J, Rockold F, Montalescot G, Cornel JH, Nicolau JC, Steg PG, Gibson CM. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes [Internet]. Circulation. 2017 ; 136( 24): e458-e459.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1161/CIR.0000000000000546
Vancouver
Roe MT, Ohman EM, Povsic TJ, White J, Rockold F, Montalescot G, Cornel JH, Nicolau JC, Steg PG, Gibson CM. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes [Internet]. Circulation. 2017 ; 136( 24): e458-e459.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1161/CIR.0000000000000546
Artigo de periodico
Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study (2013)
Kohli, Payal; Wallentin, Lars; Reyes, Eric; Horrow, Jay; Husted, Steen; Angiolillo, Dominick J.; Ardissino, Diego; Maurer, Gerald; Morais, Joao; Nicolau, José C.; Oto, Ali; Storey, Robert F.; James, Stefan K.; Cannon, Christopher P.
Fonte: Circulation. Unidade: FM
Assuntos: REVASCULARIZAÇÃO MIOCÁRDICA, DOENÇA AGUDA, INFARTO DO MIOCÁRDIO, COMORBIDADE, CHOQUE CARDIOGÊNICO, FATORES DE RISCO, ISQUEMIA, REVIDIVA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOHLI, Payal et al. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation, v. 127, n. 6, p. 673-680, 2013Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.112.124248. Acesso em: 01 nov. 2024.
APA
Kohli, P., Wallentin, L., Reyes, E., Horrow, J., Husted, S., Angiolillo, D. J., et al. (2013). Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation, 127( 6), 673-680. doi:10.1161/CIRCULATIONAHA.112.124248
NLM
Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study [Internet]. Circulation. 2013 ; 127( 6): 673-680.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.112.124248
Vancouver
Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study [Internet]. Circulation. 2013 ; 127( 6): 673-680.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.112.124248

Unidades USP

ReP

Filtros

Autores

Assuntos

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos